Kancera announces the discovery of a new class of compounds against cancer
12/04/2013
Kancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe side effects, due to poor selectivity, have limited the clinical use of HDAC inhibitors in the treatment of cancer, despite their promising treatment efficacy.
Cancer patients to travel to UF Proton Therapy Institute from Norway
12/04/2013
In an agreement with the Norway Health Authority, UF Proton Therapy Institute will treat both children and adults who have rare tumors in the nasal and sinus cavity, skull, and brain.
Risk of lethal prostate cancer in overweight patients increased by genetic mutation
12/04/2013
Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health (HSPH), Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.
Increased anal cancer risk in men with both HIV and HPV
12/04/2013
Human papillomavirus, or HPV, which can cause cervical cancer in women, is also known to cause anal cancer in both women and men. Now, a study led by researchers at the UCLA School of Nursing has found that older HIV-positive men who have sex with men are at higher risk of becoming infected with the HPVs that most often cause anal cancer.
Why a certain mutation contributes to the development of a certain cancer
12/04/2013
For the first time, researchers at Umea University have succeeded in showing how the DNA polymerase epsilon enzyme builds new genomes. The detailed image produced by these researchers shows how mutations that can contribute to the development of colorectal cancer and cervical cancer lead to changes in the structure of the protein.
Molecular imaging tracer aids in creation of treatment plans for brain metastases
12/04/2013
Imaging with the molecular imaging tracer 18F-FDOPA can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases, according to new research published in The Journal of Nuclear Medicine.
Algorithm helps identify breast cancer type
12/04/2013
Researchers from the University of Alberta and Alberta Health Services have created a computer algorithm that successfully predicts whether estrogen is sending signals to cancer cells to grow into tumours in the breast. By finding this hormone receptor, known as estrogen receptor positive, physicians can prescribe anti-estrogen drug therapies, improving patient outcomes.
New genetic links found to most common type of leukaemia
12/03/2013
Researchers have identified four new regions of the genome linked with an increase in susceptibility to chronic lymphocytic leukaemia (CLL). The findings suggest that this common type of blood cancer may develop partly as a result of faults in telomeres, sections of DNA that are vital to healthy cell division.
New breast cancer study: Results of the TARGIT-A clinical trial
12/03/2013
A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.
Predicting outcome for cancer patients receiving high-dose IL-2 therapy
12/03/2013
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment.